A database of FDA approved therapeutic peptides and proteins
ID1205 | ThPPIDTh1027 | NameInsulin Regular | Peptide SequenceA-chain:GIVEQCCTSIC< Full view | Length51 | Functional ClassificationIa | DiseaseGenetic/Hormonal | BrandHumulin R | CompanyEli Lilly and Company | Physical AppearanceSterile, clear, aqueous, and colorless solution | Route of AdministartionSubcutaneous injection in the abdominal wall, the thigh, the gluteal region or in the upper arm and Intravenousadministration of Humulin R (insulin (human recombinant)) U-100 is possible under medical supervision. | CategoryAntidiabetic Agents | TargetInsulin receptor,Insulin-like growth factor 1 receptor,Retinoblastoma-associated protein,Cathepsin D,Insulin-degrading enzyme,Neuroendocrine convertase 2,Carboxypeptidase E,Neuroendocrine convertase 1,Protein NOV homolog,Low-density lipoprotein receptor-r |
ID1206 | ThPPIDTh1027 | NameInsulin Regular | Peptide SequenceA-chain:GIVEQCCTSIC< Full view | Length51 | Functional ClassificationIa | DiseaseGenetic/Hormonal | BrandNovolin R | CompanyNovo Nordisk | Physical AppearanceSterile, clear, aqueous, and colorless solution | Route of AdministartionSubcutaneous and Intravenous infusion | CategoryAntidiabetic Agents | TargetInsulin receptor,Insulin-like growth factor 1 receptor,Retinoblastoma-associated protein,Cathepsin D,Insulin-degrading enzyme,Neuroendocrine convertase 2,Carboxypeptidase E,Neuroendocrine convertase 1,Protein NOV homolog,Low-density lipoprotein receptor-r |
ID1275 | ThPPIDTh1040 | NameInsulin Lispro | Peptide SequenceA chain:GIVEQCCTSICS Full view | Length51 | Functional ClassificationIa | DiseaseHormonal/Metabolic/genetic | BrandHumalog | CompanyEli Lilly | Physical AppearanceSterile, aqueous, clear, and colorless solution | Route of AdministartionSubcutaneous and Intravenous infusion | CategoryHypoglycemic Agents, Antidiabetic agents | TargetInsulin receptor,Insulin-like growth factor 1 receptor |
ID1276 | ThPPIDTh1040 | NameInsulin Lispro | Peptide SequenceA chain:GIVEQCCTSICS Full view | Length51 | Functional ClassificationIa | DiseaseHormonal/Metabolic/genetic | BrandHumalog KwikPen | CompanyEli Lilly | Physical AppearanceSolution | Route of AdministartionSubcutaneous injection | CategoryHypoglycemic Agents, Antidiabetic agents | TargetInsulin receptor,Insulin-like growth factor 1 receptor |
ID1277 | ThPPIDTh1040 | NameInsulin Lispro | Peptide SequenceA chain:GIVEQCCTSICS Full view | Length51 | Functional ClassificationIa | DiseaseHormonal/Metabolic/genetic | BrandHumalog Pen | CompanyEli Lilly | Physical AppearanceN.A. | Route of AdministartionN.A. | CategoryHypoglycemic Agents, Antidiabetic agents | TargetInsulin receptor,Insulin-like growth factor 1 receptor |
ID1283 | ThPPIDTh1041 | NameInsulin Glargine | Peptide SequenceA-chain:GIVEQCCTSICS Full view | Length53 | Functional ClassificationIa | DiseaseHormonal/Metabolic/genetic | BrandLantus | CompanySanofi-Aventis | Physical AppearanceSolution | Route of AdministartionSubcutaneous injection | CategoryHypoglycemic Agents, Antidiabetic agents | TargetInsulin receptor,Insulin-like growth factor 1 receptor |
ID1284 | ThPPIDTh1041 | NameInsulin Glargine | Peptide SequenceA-chain:GIVEQCCTSICS Full view | Length53 | Functional ClassificationIa | DiseaseHormonal/Metabolic/genetic | BrandLantus OptiSet | CompanyN.A. | Physical AppearanceSolution | Route of AdministartionSubcutaneous injection | CategoryHypoglycemic Agents, Antidiabetic agents | TargetInsulin receptor,Insulin-like growth factor 1 receptor |
ID1285 | ThPPIDTh1041 | NameInsulin Glargine | Peptide SequenceA-chain:GIVEQCCTSICS Full view | Length53 | Functional ClassificationIa | DiseaseHormonal/Metabolic/genetic | BrandLantus SoloStar | CompanyN.A. | Physical AppearanceSolution | Route of AdministartionSubcutaneous injection | CategoryHypoglycemic Agents, Antidiabetic agents | TargetInsulin receptor,Insulin-like growth factor 1 receptor |
ID1502 | ThPPIDTh1105 | NameInsulin Aspart | Peptide SequenceA chain: GIVEQCCTSIC Full view | Length51 | Functional ClassificationIa | DiseaseHormonal/Metabolic | BrandNovoLog | CompanyNovo Nordisk | Physical AppearanceSterile, aqueous, clear, and colorless solution | Route of AdministartionSubcutaneous injection, Intravenous injection | CategoryHypoglycemic Agents and Antidiabetic Agents | TargetInsulin receptor |
ID1503 | ThPPIDTh1105 | NameInsulin Aspart | Peptide SequenceA chain: GIVEQCCTSIC Full view | Length51 | Functional ClassificationIa | DiseaseHormonal/Metabolic | BrandNovoLog Mix 50/50 | CompanyNovo Nordisk | Physical AppearanceUniform, white, sterile suspension that contains insulin aspart | Route of AdministartionSubcutaneous injection | CategoryHypoglycemic Agents and Antidiabetic Agents | TargetInsulin receptor |
ID1504 | ThPPIDTh1105 | NameInsulin Aspart | Peptide SequenceA chain: GIVEQCCTSIC Full view | Length51 | Functional ClassificationIa | DiseaseHormonal/Metabolic | BrandNovoLog Mix 70/30 | CompanyNovo Nordisk | Physical AppearanceUniform, white, sterile suspension that contains insulin aspart 100 Units/mL. | Route of AdministartionSubcutaneous injection | CategoryHypoglycemic Agents and Antidiabetic Agents | TargetInsulin receptor |
ID1511 | ThPPIDTh1106 | NameInsulin Detemir | Peptide SequenceA chain: GIVEQCCTSIC Full view | Length51 | Functional ClassificationIa | DiseaseHormonal/Metabolic | BrandLEVEMIR | CompanyNovo Nordisk | Physical AppearanceClear, colorless, aqueous, neutral sterile solution | Route of AdministartionSubcutaneous injection | CategoryAntidiabetic Agents | TargetInsulin receptor |
ID1520 | ThPPIDTh1107 | NameInsulin Glulisine | Peptide SequenceA chain: GIVEQCCTSIC Full view | Length51 | Functional ClassificationIb | DiseaseHormonal/Metabolic | BrandAPIDRA | Companysanofi-aventis | Physical AppearanceSterile, aqueous, clear, and colorless solution | Route of AdministartionN.A. | CategoryAntidiabetic Agents | TargetInsulin receptor |
ID1634 | ThPPIDTh1140 | NameInsulin, Isophane Or Nph Insulin (Neutral Protamine Hagedorn) | Peptide SequenceA chain: GIVEQCCTSIC Full view | Length51 | Functional ClassificationIa | DiseaseHormonal/Metabolic | BrandNovolin N | CompanyNovo Nordisk | Physical AppearanceNovolin N InnoLet (nph, human insulin isophane suspension 3 ml disposable prefilled syringe) | Route of AdministartionSubcutaneous injection | CategoryHypoglycemic Agents and Antidiabetic Agents | TargetInsulin receptor |
ID1821 | ThPPIDTh1212 | NameInsulin Pork | Peptide SequenceA chain GIVEQCCTSICS Full view | Length68 | Functional ClassificationIa | DiseaseMetabolic Disorders | BrandIletin II | CompanyLilly | Physical Appearancesterile suspension | Route of AdministartionSubcutaneous | CategoryHypoglycemic Agents, Antidiabetic Agents | TargetInsulin receptor, Insulin-like growth factor 1 receptor, Insulin-degrading enzyme, HLA class II histocompatibility antigen, DQ alpha 2 chain, HLA class II histocompatibility antigen, DQ beta 1 chain, Retinoblastoma-associated protein, Cathepsin D, Carboxypeptidase E, Neuroendocrine convertase 2, Neuroendocrine convertase 1, Protein NOV homolog, Low-density lipoprotein receptor-related protein 2, Insulin-like growth factor-binding protein 7, Synaptotagmin-like protein 4, Cytochrome P450 1A2 |